CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionGross margin is 6.4%, lower than 95% of its Biotechnology peers (median 67.2%)
- FinancialsAltman Z-Score 1.09: distress zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.19%
Annual Rate
CNY 0.05Paid unknown
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Jul 16, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.77BCNY413.03M · vs all stocks (USD)
Revenue (TTM)
650.05MCNY97.00M · vs all stocks (USD)
Profit Margin
-14.62%vs Biotechnology peers
Beta
0.6010xvs all stocks
52-Week Change
20.03%vs all stocks
Forward Annual Dividend Yield
0.19%vs all stocks
Market Capitalization
2.77BCNY413.03M · vs all stocks (USD)
Enterprise Value
4.07BCNY606.74M · vs all stocks (USD)
Price to Sales (TTM)
4.26xvs Biotechnology peers
Price to Book (MRQ)
3.45xvs Biotechnology peers
Enterprise to Revenue
6.25xvs Biotechnology peers
Enterprise to EBITDA
58.95xvs Biotechnology peers
Gross Margin
6.38%vs Biotechnology peers
Profit Margin
-14.62%vs Biotechnology peers
Operating Margin
-10.66%vs Biotechnology peers
Return on Assets (TTM)
-1.35%vs Biotechnology peers
Return on Equity (TTM)
-11.28%vs Biotechnology peers
Revenue (TTM)
650.05MCNY97.00M · vs all stocks (USD)
Revenue per Share (TTM)
5.63CNYUpdated Sep 21, 2026Quarterly Revenue Growth
13.00%vs Biotechnology peers
Gross Profit (TTM)
63.42MCNY9.46M · vs all stocks (USD)
EBITDA (TTM)
75.91MCNY11.33M · vs all stocks (USD)
Net Income (TTM)
-95.05MCNY-14.18M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
32.41%vs Biotechnology peers
Operating Cash Flow (TTM)
69.31MCNY10.34M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-63.80MCNY-9.52M · vs all stocks (USD)
Forward Annual Dividend Rate
0.0500CNYUpdated Sep 21, 2026Forward Annual Dividend Yield
0.19%vs all stocks
Trailing Annual Dividend Rate
0.0450CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
0.19%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
83.14MCNYFY2025 · Dec 31, 2025Revenue
606.18MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
522.68MCNYFY2025 · Dec 31, 2025Gross Profit
83.50MCNYFY2025 · Dec 31, 2025Operating Income
-33.58MCNY-5.01M · vs all stocks (USD)
Pre-tax Income
-105.21MCNYFY2025 · Dec 31, 2025Income Tax Expense
-23.49MCNYFY2025 · Dec 31, 2025Net Income
-81.73MCNYFY2025 · Dec 31, 2025EBIT
-57.48MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
75.91MCNYFY2025 · Dec 31, 2025Research & Development
69.85MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
23.57MCNYFY2025 · Dec 31, 2025Other Operating Expenses
1.54MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
796.40KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
47.73MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.6400CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.6400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
114.62MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
114.62MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-81.73MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
8.37MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-129.32MCNYFY2025 · Dec 31, 2025Free Cash Flow
-295.47MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
65.14MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-81.73MCNYFY2025 · Dec 31, 2025Other Non-cash Items
50.97MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
25.47MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-124.03MCNYFY2025 · Dec 31, 2025Capital Expenditures
-166.14MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-166.14MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
468.38MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-326.06MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-29.83MCNYFY2025 · Dec 31, 2025Other Financing Charges
-22.30MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
90.19MCNYFY2025 · Dec 31, 2025Shares Outstanding
115.28MSharesUpdated Sep 21, 2026Float Shares
56.47MSharesUpdated Sep 21, 2026% Held by Insiders
52.69%vs all stocks
% Held by Institutions
5.02%vs all stocks
Total Cash (MRQ)
76.06MCNY11.35M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.6660CNYUpdated Sep 21, 2026Total Debt (MRQ)
1.32BCNY197.30M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.52xvs Biotechnology peers
Current Ratio (MRQ)
0.9280xvs Biotechnology peers
Book Value per Share (MRQ)
6.96CNYUpdated Sep 21, 2026Total Assets
2.85BCNY425.38M · vs all stocks (USD)
Total Current Assets
770.29MCNYFY2025 · Dec 31, 2025Total Liabilities
1.94BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.08BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.12BCNYFY2025 · Dec 31, 2025Total Current Liabilities
822.08MCNYFY2025 · Dec 31, 2025Cash
65.14MCNYFY2025 · Dec 31, 2025Cash Equivalents
20.71MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
85.85MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.01KCNYFY2025 · Dec 31, 2025Accounts Receivable
159.35MCNYFY2025 · Dec 31, 2025Inventory
473.76MCNYFY2025 · Dec 31, 2025Accounts Payable
461.26MCNYFY2025 · Dec 31, 2025Short-term Debt
325.10MCNYFY2025 · Dec 31, 2025Other Current Liabilities
17.70MCNYFY2025 · Dec 31, 2025Long-term Debt
974.16MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
24.94KCNYFY2025 · Dec 31, 2025Common Stock (Book)
115.28MCNYFY2025 · Dec 31, 2025Retained Earnings
217.46MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
909.36MCNY135.69M · vs all stocks (USD)
Treasury Stock
21.97MCNYFY2025 · Dec 31, 202552-Week Low
18.44CNYUpdated Sep 21, 202652-Week High
32.58CNYUpdated Sep 21, 202652-Week Change
20.03%vs all stocks
Beta
0.6010xvs all stocks
50-Day MA
24.70CNYUpdated Sep 21, 2026200-Day MA
23.59CNYUpdated Sep 21, 2026Avg 10-Day Volume
1.80MSharesUpdated Sep 21, 2026Avg 30-Day Volume
2.33MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-0.8300CNYUpdated Sep 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 6.4%, lower than 95% of its Biotechnology peers (median 67.2%)Significant
Gross margin: 0.06Industry median: 0.67Industry P5: 0.14Peers compared: 260
Current ratio is 0.93×, lower than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 0.93Industry median: 5.71Industry P5: 1.02Peers compared: 260
Debt-to-equity is 1.52×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 1.52Industry median: 0.07Industry P95: 0.93Peers compared: 260
Financial Health
Altman Z-Score 1.09: distress zoneCritical
Altman Z-Score: 1.09
Low earnings qualitySignificant
Earnings Quality Score: -1.14
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Novartis India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Anhui Fengyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tellgen Corporation
Tier 1ProductionApproval-Gated PipelineRule
Allgens Medical Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aarti Drugs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Relmada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Canopus Wisdom MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Orum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule